Related Experiment Videos
[Treatment of the patient with ideal LDL cholesterol]
1Departamento de Endocrinología del Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, 14080 México, D.F. emendozap@yahoo.com.mx
Insights
Coronary heart disease remains a global threat. This review explores alternative therapies for patients with on-target LDL-C, as cardiovascular risk persists despite statin treatment.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Context:
- Coronary heart disease (CHD) is the leading global cause of mortality.
- Low-density lipoprotein-cholesterol (LDL-C) reduction is crucial for cardiovascular prevention.
- Statins effectively lower LDL-C and reduce coronary event risks, but residual risk remains.
Purpose:
- To review alternative therapeutic approaches for managing cardiovascular risk.
- To identify treatment options for patients with on-target LDL-C levels.
- To address the unmet need for further risk reduction in high-risk individuals.
Summary:
- Despite statin therapy, cardiovascular risk can remain high in patients achieving target LDL-C levels.
- This review examines alternative strategies beyond current LDL-C lowering therapies.
- Focus is placed on novel approaches and treatment modifications for enhanced risk management.
Impact:
- Provides clinicians with insights into managing persistent cardiovascular risk.
- Highlights the importance of exploring diverse therapeutic avenues.
- Aims to improve patient outcomes by addressing residual risk factors in coronary heart disease.
Abstract:
Coronary heart disease (CHD) is the leading cause of death worldwide. Low-density lipoprotein-cholesterol (LDL-C) reduction is the corner-stone in both primary and secondary cardiovascular prevention. Use of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors (statins) has proved to reduce LDL-C levels and major coronary event risks. The benefit on cardiovascular risk reduction is greater as LDL-C lowering is greater. Cardiovascular risk remains unacceptably high, even in patients with on-target LDL-C. This paper presents a review of alternatives for both approach and therapy in patients with on-target LDL-C.